Objectives: Polycystic ovarian syndrome (PCOS) is most frequent among women of reproductive age and causes anovulatory infertility. Serum Anti Mullerian hormone (AMH) level is known to be elevated in women with polycystic ovarian syndrome (PCOS), it to be used as a diagnostic marker for PCOS. Aim: This study has been done to determine whether the measurement of serum AMH can be used to diagnose PCOS and as a tool to predict the prognosis of PCOS. Methods: This was a prospective case control study, comprised of 80 women diagnosed with PCOS using Rotterdam criteria and 80 non PCOS controls. Clinical data were collected including history, oligomenorrhea, hirsutism, examination included BMI and blood investigations including serum FSH, LH, TSH, prolactin, estradiol and serum AMH level. Results: There is no significant difference was seen in age, BMI and socio-economic status among PCOS cases and non PCOS group (p>0.05). Mean level of AMH in PCOS cases and controls was 8.73 and 5.67 respectively, AMH was significantly higher in women with PCOS than non PCOS women (p<0.05). Serum LH and LH/FSH ratio was significantly higher in the PCOS group than in the control group (p < 0.001), whereas serum FSH, estradiol and prolactin level not significantly differ in PCOS and non PCOS group (p>0.05). Conclusion: AMH level can be used as diagnostic and prognostic modalities in PCOS. AMH as an independent marker could not effectively diagnose PCOS